Cargando…

Attenuation of airway inflammation by simvastatin and the implications for asthma treatment: is the jury still out?

Although some studies have explained the immunomodulatory effects of statins, the exact mechanisms and the therapeutic significance of these molecules remain to be elucidated. This study not only evaluated the therapeutic potential and inhibitory mechanism of simvastatin in an ovalbumin (OVA)-specif...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jing-Nan, Suh, Dong-Hyeon, Yang, Eun-Mi, Lee, Seung-Ihm, Park, Hae-Sim, Shin, Yoo Seob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183942/
https://www.ncbi.nlm.nih.gov/pubmed/25213768
http://dx.doi.org/10.1038/emm.2014.55
_version_ 1782337766554599424
author Liu, Jing-Nan
Suh, Dong-Hyeon
Yang, Eun-Mi
Lee, Seung-Ihm
Park, Hae-Sim
Shin, Yoo Seob
author_facet Liu, Jing-Nan
Suh, Dong-Hyeon
Yang, Eun-Mi
Lee, Seung-Ihm
Park, Hae-Sim
Shin, Yoo Seob
author_sort Liu, Jing-Nan
collection PubMed
description Although some studies have explained the immunomodulatory effects of statins, the exact mechanisms and the therapeutic significance of these molecules remain to be elucidated. This study not only evaluated the therapeutic potential and inhibitory mechanism of simvastatin in an ovalbumin (OVA)-specific asthma model in mice but also sought to clarify the future directions indicated by previous studies through a thorough review of the literature. BALB/c mice were sensitized to OVA and then administered three OVA challenges. On each challenge day, 40 mg kg(−1) simvastatin was injected before the challenge. The airway responsiveness, inflammatory cell composition, and cytokine levels in bronchoalveolar lavage (BAL) fluid were assessed after the final challenge, and the T cell composition and adhesion molecule expression in lung homogenates were determined. The administration of simvastatin decreased the airway responsiveness, the number of airway inflammatory cells, and the interleukin (IL)-4, IL-5 and IL-13 concentrations in BAL fluid compared with vehicle-treated mice (P<0.05). Histologically, the number of inflammatory cells and mucus-containing goblet cells in lung tissues also decreased in the simvastatin-treated mice. Flow cytometry showed that simvastatin treatment significantly reduced the percentage of pulmonary CD4(+) cells and the CD4(+)/CD8(+) T-cell ratio (P<0.05). Simvastatin treatment also decreased the expression of the vascular cell adhesion molecule 1 and intercellular adhesion molecule 1 proteins, as measured in homogenized lung tissues (P<0.05) and human epithelial cells. The reduction in the T cell influx as a result of the decreased expression of cell adhesion molecules is one of the mechanisms by which simvastatin attenuates airway responsiveness and allergic inflammation. Rigorous review of the literature together with our findings suggested that simvastatin should be further developed as a potential therapeutic strategy for allergic asthma.
format Online
Article
Text
id pubmed-4183942
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-41839422014-10-03 Attenuation of airway inflammation by simvastatin and the implications for asthma treatment: is the jury still out? Liu, Jing-Nan Suh, Dong-Hyeon Yang, Eun-Mi Lee, Seung-Ihm Park, Hae-Sim Shin, Yoo Seob Exp Mol Med Original Article Although some studies have explained the immunomodulatory effects of statins, the exact mechanisms and the therapeutic significance of these molecules remain to be elucidated. This study not only evaluated the therapeutic potential and inhibitory mechanism of simvastatin in an ovalbumin (OVA)-specific asthma model in mice but also sought to clarify the future directions indicated by previous studies through a thorough review of the literature. BALB/c mice were sensitized to OVA and then administered three OVA challenges. On each challenge day, 40 mg kg(−1) simvastatin was injected before the challenge. The airway responsiveness, inflammatory cell composition, and cytokine levels in bronchoalveolar lavage (BAL) fluid were assessed after the final challenge, and the T cell composition and adhesion molecule expression in lung homogenates were determined. The administration of simvastatin decreased the airway responsiveness, the number of airway inflammatory cells, and the interleukin (IL)-4, IL-5 and IL-13 concentrations in BAL fluid compared with vehicle-treated mice (P<0.05). Histologically, the number of inflammatory cells and mucus-containing goblet cells in lung tissues also decreased in the simvastatin-treated mice. Flow cytometry showed that simvastatin treatment significantly reduced the percentage of pulmonary CD4(+) cells and the CD4(+)/CD8(+) T-cell ratio (P<0.05). Simvastatin treatment also decreased the expression of the vascular cell adhesion molecule 1 and intercellular adhesion molecule 1 proteins, as measured in homogenized lung tissues (P<0.05) and human epithelial cells. The reduction in the T cell influx as a result of the decreased expression of cell adhesion molecules is one of the mechanisms by which simvastatin attenuates airway responsiveness and allergic inflammation. Rigorous review of the literature together with our findings suggested that simvastatin should be further developed as a potential therapeutic strategy for allergic asthma. Nature Publishing Group 2014-09 2014-09-12 /pmc/articles/PMC4183942/ /pubmed/25213768 http://dx.doi.org/10.1038/emm.2014.55 Text en Copyright © 2014 KSBMB. http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Original Article
Liu, Jing-Nan
Suh, Dong-Hyeon
Yang, Eun-Mi
Lee, Seung-Ihm
Park, Hae-Sim
Shin, Yoo Seob
Attenuation of airway inflammation by simvastatin and the implications for asthma treatment: is the jury still out?
title Attenuation of airway inflammation by simvastatin and the implications for asthma treatment: is the jury still out?
title_full Attenuation of airway inflammation by simvastatin and the implications for asthma treatment: is the jury still out?
title_fullStr Attenuation of airway inflammation by simvastatin and the implications for asthma treatment: is the jury still out?
title_full_unstemmed Attenuation of airway inflammation by simvastatin and the implications for asthma treatment: is the jury still out?
title_short Attenuation of airway inflammation by simvastatin and the implications for asthma treatment: is the jury still out?
title_sort attenuation of airway inflammation by simvastatin and the implications for asthma treatment: is the jury still out?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183942/
https://www.ncbi.nlm.nih.gov/pubmed/25213768
http://dx.doi.org/10.1038/emm.2014.55
work_keys_str_mv AT liujingnan attenuationofairwayinflammationbysimvastatinandtheimplicationsforasthmatreatmentisthejurystillout
AT suhdonghyeon attenuationofairwayinflammationbysimvastatinandtheimplicationsforasthmatreatmentisthejurystillout
AT yangeunmi attenuationofairwayinflammationbysimvastatinandtheimplicationsforasthmatreatmentisthejurystillout
AT leeseungihm attenuationofairwayinflammationbysimvastatinandtheimplicationsforasthmatreatmentisthejurystillout
AT parkhaesim attenuationofairwayinflammationbysimvastatinandtheimplicationsforasthmatreatmentisthejurystillout
AT shinyooseob attenuationofairwayinflammationbysimvastatinandtheimplicationsforasthmatreatmentisthejurystillout